Schonfeld Strategic Advisors LLC Zymeworks Inc. Transaction History

Schonfeld Strategic Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$4.82 - $7.7 $362,464 - $579,040	-75,200 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$6.0 - $16.98 $451,200 - $1.28 Million	75,200 New	75,200 $493,000
Q2 2021 Aug 16, 2021	SELL	$26.5 - $38.23 $445,650 - $642,913	-16,817 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$29.83 - $56.81 $501,651 - $955,373	16,817 New	16,817 $531,000
Q4 2020 Feb 16, 2021	SELL	$39.12 - $54.99 $913,569 - $1.28 Million	-23,353 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$29.21 - $46.58 $501,331 - $799,452	17,163 Added 277.27%	23,353 $1,000
Q2 2020 Aug 14, 2020	BUY	$33.67 - $40.0 $208,417 - $247,600	6,190 New	6,190 $223,000
Q3 2019 Nov 14, 2019	SELL	$22.78 - $29.08 $1.8 Million - $2.3 Million	-79,200 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$15.0 - $22.49 $1.19 Million - $1.78 Million	79,200 New	79,200 $1.74 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $872M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.